Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DP-QB-PSA-005 + DP-QB-STA-005
- Development stage
- Unknown
- Lead developer
- Ottawa Hospital Research Institute
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intraarticular
01
Overview
DP-QB-PSA-005 + DP-QB-STA-005 is an experimental combination of two bacteriophage cocktails being investigated for the treatment of periprosthetic joint infections (PJI). DP-QB-PSA-005 is a cocktail of phages specifically targeting *Pseudomonas aeruginosa*, while DP-QB-STA-005 is a cocktail targeting *Staphylococcus aureus*. These cocktails are designed for intra-articular administration as an adjunct to the Debridement Antibiotic and Implant Retention (DAIR) procedure and systemic antibiotic therapy. Bacteriophages are viruses that infect and lyse specific bacterial species, offering a mechanism to disrupt biofilms on prosthetic surfaces that are often recalcitrant to conventional antibiotics. The therapy is currently being evaluated in the DePHEAT-PJI clinical trial led by the Ottawa Hospital Research Institute.
- Other names
- DePHEAT-PJI phage cocktailPseudomonas aeruginosa phage cocktail DP-QB-PSA-005Staphylococcus aureus phage cocktail DP-QB-STA-005
02
Targets
Transcription factor p65/14-3-3 protein-protein interaction complex
Beyond the preview
Go deeper on DP-QB-PSA-005 + DP-QB-STA-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DP-QB-PSA-005 + DP-QB-STA-005.